E2F1 and cancer: Although targeting RB1 loss or E2F1 has long been considered a promising strategy for cancer therapy,14,39 currently, there are no agents that directly target RB1/E2F1 in the market due to their undruggable characteristics as well as their general roles in biological processes in the healthy body.